Do analysts recommend RNAZ or BCLI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Brainstorm Cell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher earnings and valuation, RNAZ or BCLI?

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A Brainstorm Cell Therapeutics N/A N/A -$11.62M -$1.65 N/A

Is RNAZ or BCLI more profitable?

Brainstorm Cell Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Brainstorm Cell Therapeutics N/A N/A -519.50%

Does the media prefer RNAZ or BCLI?

In the previous week, TransCode Therapeutics had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Brainstorm Cell Therapeutics. TransCode Therapeutics' average media sentiment score of 1.89 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Brainstorm Cell Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate RNAZ or CMMB?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Chemomab Therapeutics 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Which has higher valuation and earnings, RNAZ or CMMB?

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A Chemomab Therapeutics N/A N/A -$8.99M -$2.13 N/A

Is RNAZ or CMMB more profitable?

Chemomab Therapeutics' return on equity of -92.14% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Chemomab Therapeutics N/A -92.14% -82.05%

Does the media prefer RNAZ or CMMB?

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 2 articles in the media. TransCode Therapeutics' average media sentiment score of 1.89 beat Chemomab Therapeutics' score of 1.87 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Chemomab Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Do analysts rate RNAZ or PHIO?

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,184.40%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, RNAZ or PHIO?

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A Phio Pharmaceuticals N/A N/A -$8.70M -$1.29 N/A

Is RNAZ or PHIO more profitable?

Phio Pharmaceuticals' return on equity of -87.41% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% Phio Pharmaceuticals N/A -87.41% -79.76%

Does the media favor RNAZ or PHIO?

In the previous week, Phio Pharmaceuticals had 6 more articles in the media than TransCode Therapeutics. MarketBeat recorded 8 mentions for Phio Pharmaceuticals and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.89 beat Phio Pharmaceuticals' score of -0.37 indicating that TransCode Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Phio Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts recommend RNAZ or OSRH?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 OSR 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer RNAZ or NRSN?

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 1,898.12%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than TransCode Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score TransCode Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 NeuroSense Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 1 Strong Buy rating(s) 2.60

Which has preferable valuation & earnings, RNAZ or NRSN?

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio TransCode Therapeutics N/A N/A -$34.66M -$52.37 N/A NeuroSense Therapeutics N/A N/A -$11.12M -$0.54 N/A

Is RNAZ or NRSN more profitable?

NeuroSense Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets TransCode Therapeutics N/A -875.35% -37.46% NeuroSense Therapeutics N/A N/A N/A

Does the media refer more to RNAZ or NRSN?

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 2 articles in the media. TransCode Therapeutics' average media sentiment score of 1.89 equaled NeuroSense Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment TransCode Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive NeuroSense Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

TransCode Therapeutics (RNAZ) Competitors

$2.14 -0.04 (-1.83%)

As of 12:49 PM Eastern

Compare

RNAZ vs. BCLI, CMMB, PHIO, OSRH, and NRSN

Should you buy TransCode Therapeutics stock or one of its competitors? TransCode Therapeutics's main competitors and comparable companies include Brainstorm Cell Therapeutics (BCLI), Chemomab Therapeutics (CMMB), Phio Pharmaceuticals (PHIO), OSR (OSRH), and NeuroSense Therapeutics (NRSN). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does TransCode Therapeutics compare to Brainstorm Cell Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Brainstorm Cell Therapeutics (NASDAQ:BCLI) are both small-cap healthcare companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, risk, media sentiment, valuation, earnings, profitability and institutional ownership.

Brainstorm Cell Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Brainstorm Cell Therapeutics	N/A	N/A	-$11.62M	-$1.65	N/A

14.3% of Brainstorm Cell Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 11.2% of Brainstorm Cell Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Brainstorm Cell Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Brainstorm Cell Therapeutics	N/A	N/A	-519.50%

In the previous week, TransCode Therapeutics had 1 more articles in the media than Brainstorm Cell Therapeutics. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for Brainstorm Cell Therapeutics. TransCode Therapeutics' average media sentiment score of 1.89 beat Brainstorm Cell Therapeutics' score of 0.34 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Brainstorm Cell Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Brainstorm Cell Therapeutics	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

TransCode Therapeutics has a beta of 1.24, indicating that its share price is 24% more volatile than the broader market. Comparatively, Brainstorm Cell Therapeutics has a beta of 0.23, indicating that its share price is 77% less volatile than the broader market.

Summary

TransCode Therapeutics beats Brainstorm Cell Therapeutics on 6 of the 11 factors compared between the two stocks.

How does TransCode Therapeutics compare to Chemomab Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and Chemomab Therapeutics (NASDAQ:CMMB) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, earnings, media sentiment, analyst recommendations, institutional ownership, profitability, valuation and risk.

46.1% of Chemomab Therapeutics shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by company insiders. Comparatively, 11.9% of Chemomab Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TransCode Therapeutics has a beta of 1.24, suggesting that its stock price is 24% more volatile than the broader market. Comparatively, Chemomab Therapeutics has a beta of 0.65, suggesting that its stock price is 35% less volatile than the broader market.

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 2 articles in the media. TransCode Therapeutics' average media sentiment score of 1.89 beat Chemomab Therapeutics' score of 1.87 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Chemomab Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Chemomab Therapeutics' return on equity of -92.14% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Chemomab Therapeutics	N/A	-92.14%	-82.05%

Chemomab Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Chemomab Therapeutics	N/A	N/A	-$8.99M	-$2.13	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Chemomab Therapeutics	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Summary

Chemomab Therapeutics beats TransCode Therapeutics on 6 of the 10 factors compared between the two stocks.

How does TransCode Therapeutics compare to Phio Pharmaceuticals?

TransCode Therapeutics (NASDAQ:RNAZ) and Phio Pharmaceuticals (NASDAQ:PHIO) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

TransCode Therapeutics has a beta of 1.24, indicating that its stock price is 24% more volatile than the broader market. Comparatively, Phio Pharmaceuticals has a beta of 0.82, indicating that its stock price is 18% less volatile than the broader market.

57.3% of Phio Pharmaceuticals shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 3.5% of Phio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A

In the previous week, Phio Pharmaceuticals had 6 more articles in the media than TransCode Therapeutics. MarketBeat recorded 8 mentions for Phio Pharmaceuticals and 2 mentions for TransCode Therapeutics. TransCode Therapeutics' average media sentiment score of 1.89 beat Phio Pharmaceuticals' score of -0.37 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Phio Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Phio Pharmaceuticals has a consensus price target of $14.00, suggesting a potential upside of 1,184.40%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Phio Pharmaceuticals' return on equity of -87.41% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
Phio Pharmaceuticals	N/A	-87.41%	-79.76%

Summary

Phio Pharmaceuticals beats TransCode Therapeutics on 9 of the 13 factors compared between the two stocks.

How does TransCode Therapeutics compare to OSR?

TransCode Therapeutics (NASDAQ:RNAZ) and OSR (NASDAQ:OSRH) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, earnings, dividends, profitability, analyst recommendations, valuation and risk.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
OSR	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

In the previous week, TransCode Therapeutics had 1 more articles in the media than OSR. MarketBeat recorded 2 mentions for TransCode Therapeutics and 1 mentions for OSR. TransCode Therapeutics' average media sentiment score of 1.89 beat OSR's score of 0.93 indicating that TransCode Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
TransCode Therapeutics	Very Positive
OSR	Positive

TransCode Therapeutics has a beta of 1.24, meaning that its share price is 24% more volatile than the broader market. Comparatively, OSR has a beta of 0.56, meaning that its share price is 44% less volatile than the broader market.

55.3% of OSR shares are held by institutional investors. 0.1% of TransCode Therapeutics shares are held by insiders. Comparatively, 36.9% of OSR shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

TransCode Therapeutics has a net margin of 0.00% compared to OSR's net margin of -593.15%. OSR's return on equity of -8.36% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
OSR	-593.15%	-8.36%	-6.24%

OSR has higher revenue and earnings than TransCode Therapeutics. OSR is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
OSR	$1.81M	5.18	-$27.06M	-$0.37	N/A

Summary

OSR beats TransCode Therapeutics on 7 of the 12 factors compared between the two stocks.

How does TransCode Therapeutics compare to NeuroSense Therapeutics?

TransCode Therapeutics (NASDAQ:RNAZ) and NeuroSense Therapeutics (NASDAQ:NRSN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, dividends, valuation, earnings, profitability, risk, institutional ownership and media sentiment.

TransCode Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, NeuroSense Therapeutics has a beta of 1.62, meaning that its stock price is 62% more volatile than the broader market.

NeuroSense Therapeutics has a consensus target price of $8.50, suggesting a potential upside of 1,898.12%. Given NeuroSense Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe NeuroSense Therapeutics is more favorable than TransCode Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
TransCode Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
NeuroSense Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

1.0% of NeuroSense Therapeutics shares are owned by institutional investors. 0.1% of TransCode Therapeutics shares are owned by insiders. Comparatively, 27.4% of NeuroSense Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, TransCode Therapeutics and TransCode Therapeutics both had 2 articles in the media. TransCode Therapeutics' average media sentiment score of 1.89 equaled NeuroSense Therapeutics'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
TransCode Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
NeuroSense Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

NeuroSense Therapeutics is trading at a lower price-to-earnings ratio than TransCode Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
TransCode Therapeutics	N/A	N/A	-$34.66M	-$52.37	N/A
NeuroSense Therapeutics	N/A	N/A	-$11.12M	-$0.54	N/A

NeuroSense Therapeutics' return on equity of 0.00% beat TransCode Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
TransCode Therapeutics	N/A	-875.35%	-37.46%
NeuroSense Therapeutics	N/A	N/A	N/A

Summary

NeuroSense Therapeutics beats TransCode Therapeutics on 11 of the 12 factors compared between the two stocks.

Get TransCode Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RNAZ and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

RNAZ vs. The Competition

Export

Metric	TransCode Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$36.23M	$3.92B	$7.13B	$12.81B
Dividend Yield	N/A	3.61%	2.54%	11.27%
P/E Ratio	-0.04	11.77	272.85	25.45
Price / Sales	N/A	1,393.83	685.78	122.48
Price / Cash	N/A	44.06	28.74	36.03
Price / Book	0.19	16.75	11.02	6.33
Net Income	-$34.66M	-$22.71M	$3.47B	$349.46M
7 Day Performance	-20.74%	2.15%	0.94%	-0.29%
1 Month Performance	-53.07%	12.31%	7.93%	4.18%
1 Year Performance	-78.01%	53.90%	23.74%	14.53%

TransCode Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
RNAZ TransCode Therapeutics	0.8522 of 5 stars	$2.14 -1.8%	N/A	-77.6%	$36.23M	N/A	N/A	9	News Coverage Positive News Gap Down High Trading Volume
BCLI Brainstorm Cell Therapeutics	N/A	$1.23 -12.8%	N/A	+48.0%	$14.00M	N/A	N/A	40	Gap Down High Trading Volume
CMMB Chemomab Therapeutics	1.4929 of 5 stars	$1.94 +1.6%	$25.00 +1,188.7%	-13.7%	$13.97M	N/A	N/A	20	News Coverage Positive News
PHIO Phio Pharmaceuticals	3.7503 of 5 stars	$1.16 +10.0%	$14.00 +1,112.1%	-42.6%	$13.42M	N/A	N/A	10	News Coverage Positive News Analyst Revision
OSRH OSR	0.6709 of 5 stars	$0.38 -12.1%	N/A	-66.5%	$13.21M	$2.63M	N/A	N/A	High Trading Volume

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:RNAZ) was last updated on 8/31/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. BCLI, CMMB, PHIO, OSRH, and NRSN

How does TransCode Therapeutics compare to Brainstorm Cell Therapeutics?

Summary

How does TransCode Therapeutics compare to Chemomab Therapeutics?

Summary

How does TransCode Therapeutics compare to Phio Pharmaceuticals?

Summary

How does TransCode Therapeutics compare to OSR?

Summary

How does TransCode Therapeutics compare to NeuroSense Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

TransCode Therapeutics (RNAZ) Competitors

RNAZ vs. BCLI, CMMB, PHIO, OSRH, and NRSN

How does TransCode Therapeutics compare to Brainstorm Cell Therapeutics?

Which has higher earnings and valuation, RNAZ or BCLI?

Do insiders & institutionals have more ownership in RNAZ or BCLI?

Is RNAZ or BCLI more profitable?

Does the media prefer RNAZ or BCLI?

Do analysts recommend RNAZ or BCLI?

Which has more risk and volatility, RNAZ or BCLI?

Summary

How does TransCode Therapeutics compare to Chemomab Therapeutics?

Do insiders and institutionals hold more shares of RNAZ or CMMB?

Which has more risk and volatility, RNAZ or CMMB?

Does the media prefer RNAZ or CMMB?

Is RNAZ or CMMB more profitable?

Which has higher valuation and earnings, RNAZ or CMMB?

Do analysts rate RNAZ or CMMB?

Summary

How does TransCode Therapeutics compare to Phio Pharmaceuticals?

Which has more risk & volatility, RNAZ or PHIO?

Do institutionals and insiders believe in RNAZ or PHIO?

Which has higher earnings and valuation, RNAZ or PHIO?

Does the media favor RNAZ or PHIO?

Do analysts rate RNAZ or PHIO?

Is RNAZ or PHIO more profitable?

Summary

How does TransCode Therapeutics compare to OSR?

Do analysts recommend RNAZ or OSRH?

Does the media favor RNAZ or OSRH?

Which has more risk and volatility, RNAZ or OSRH?

Do institutionals & insiders have more ownership in RNAZ or OSRH?

Is RNAZ or OSRH more profitable?

Which has stronger valuation and earnings, RNAZ or OSRH?

Summary

How does TransCode Therapeutics compare to NeuroSense Therapeutics?

Which has more risk & volatility, RNAZ or NRSN?

Do analysts prefer RNAZ or NRSN?

Do institutionals & insiders hold more shares of RNAZ or NRSN?

Does the media refer more to RNAZ or NRSN?

Which has preferable valuation & earnings, RNAZ or NRSN?

Is RNAZ or NRSN more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

RNAZ vs. The Competition

TransCode Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools